Q-omics provides the consensus-scored RBBP4P3 profile across patient tissues and cancer cell-line models. RBBP4P3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RBBP4P3 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, RBBP4P3 RNA expression shows 10,049 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KICH, LIHC, and DLBC as cancer lineages where RBBP4P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBBP4P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBBP4P3 survival associations across molecular data types. RBBP4P3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBBP4P3 RNA expression–survival associations across cancer types. High RBBP4P3 expression shows unfavorable associations in KICH, HNSC, DLBC and SARC, but favorable associations in CESC and UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KICH as the clearest survival context for RBBP4P3 RNA expression.
This table summarizes RBBP4P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RBBP4P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBBP4P3 shows lower tumor expression in READ and higher tumor expression in LIHC, LUAD, READ, CHOL and BRCA. The LIHC box plot shows higher RBBP4P3 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .001).
This table shows molecular features associated with RBBP4P3 in patient tissues and cancer cell lines. In patient samples, RBBP4P3 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
